A randomized controlled trial involving patients with stage 3b chronic kidney disease from primary care reported that in contrast to reported cardiorenal protective effects of nonsteroidal ...
Dr. David Bearss, CEO and Co-founder of Halia Therapeutics has been named an honoree of the 2024 PharmaVoice 100 list in the Standout Leaders category. This prestigious recognition spotlights the most ...